GlassScriptPhysician profile
Hugo A Rojas
NPI 1508978214
$7,158.09
in general payments reported to CMS, 2019-2025
43 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $827 · 2021: $1,158 · 2022: $1,453 · 2023: $1,201 · 2024: $891 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116 · Travel and Lodging: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.47 |
| Travel and Lodging | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,199.93 | 2019-2023 | Xeomin |
| Lilly USA, LLC | $872.76 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $660.44 | 2021-2025 | Vraylar, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals LP | $637.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.62 | 2021-2024 | Cycloset |
| Allergan, INC. | $379.73 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $355.16 | 2020-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $344.95 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $282.10 | 2022-2023 | |
| Novo Nordisk INC | $244.19 | 2019-2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.79 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $147.93 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $140.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.95 | 2019-2025 | Jardiance |
| Axsome Therapeutics, INC. | $93.64 | 2024 | Auvelity |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $89.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $70.76 | 2020-2025 | |
| Mdd US Operations, LLC | $68.26 | 2020 | |
| Medtronic, INC. | $60.05 | 2021 | |
| Lundbeck LLC | $56.65 | 2022-2025 | Abilify Asimtufii |
| Sanofi-Aventis U.S. LLC | $54.15 | 2020-2021 | |
| United Imaging Healthcare North America, INC. | $53.66 | 2025 | Umr, Umr 680 |
| Abbott Laboratories | $48.51 | 2022-2023 | Proclaim |
| Vanda Pharmaceuticals INC. | $36.69 | 2023-2024 | Fanapt, Hetlioz |
| Kowa Pharmaceuticals America, INC. | $34.12 | 2022 | |
| Galderma Laboratories, L.P. | $33.35 | 2019 | |
| Dexcom, INC. | $31.92 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $31.40 | 2025 | Austedo Xr |
| Atland Pharmaceuticals, LLC | $30.77 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Astellas Pharma US INC | $29.76 | 2019-2020 | |
| Amarin Pharma, INC. | $28.78 | 2019 | |
| Sebela Pharmaceuticals INC. | $27.63 | 2019 | |
| Medtronic USA, INC. | $23.38 | 2020 | |
| Alk-Abello, INC | $21.98 | 2024 | Odactra, Ragwitek, Grastek |
| Globus Medical, INC. | $20.43 | 2025 | Senza |
| Axonics, INC. | $18.81 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.18 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $16.56 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.34 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.61 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.30 | 2020 | |
| Merck Sharp & Dohme LLC | $11.91 | 2020 | |
| Esperion Therapeutics, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.